Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its key product, NERLYNX (neratinib), treats HER2-positive breast cancer, while in-licensed alisertib targets Aurora Kinase A for various cancers. The company emphasizes targeted therapies, clinical development, and strategic licensing to address unmet needs in oncology markets worldwide. Its business model combines direct sales, licensing, and partnerships to advance cancer treatment options.
This description was generated via AI from an annual report. Updated about 1 year ago.